SUMMIT, NJ (TheStreet) -- Celgene: Beat and raise again, but in-line sales of the cancer drug Revlimid may disappoint. Celgene's adjusted earnings rose by a better-than-expected 36% in the third quarter, driven by strong drug sales and a lower share count. Sales of the multiple myeloma drug Revlimid totaled $820 million, in line with consensus of around $818 million. Like it did after the second quarter, Celgene once again raised financial guidance above current consensus for the remainder of the year to adjusted earnings between $3.78 and $3.80 per share from adjusted earnings in the range of $3.45 to $3.55 per share. ... Click to view a price quote on CELG. Click to research the Drugs industry.